On July 29, Gelonghui, Fuhong, Hanlin-B (2696.HK) accelerated in the afternoon. It is now reported at HK$59.55, an increase of 7.59%, with the latest total market value of HK$32.37 billion. The company announced at noon that recently, marketing authorization applications for HLX02 (injectable trastuzumab) for HER2-positive early-stage breast cancer, HER2-positive metastatic breast cancer, and untreated HER2-positive metastatic gastric cancer or gastroesophageal adenocarcinoma treatment submitted by a wholly-owned subsidiary of the company's business partner were approved by the European Commission. Following this approval, HLX02 has obtained a centralized listing license in all EU member states as well as Iceland, Liechtenstein, and Norway (each in the European Economic Area (EEA)).